Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Shaman inverts its drug development model


Shaman inverts its drug development model

With its long-term capital security in mind, Shaman Pharmaceuticals Inc. has decided to focus on the pharmaceutical industry as its primary customer and will concentrate its development efforts in diseases best modeled by whole animal testing.

Although the South San Francisco company last week said it will

Read the full 554 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers